Want to see JP:4584 full AI Analyst Report?
Kidswell Bio Corporation (4584) Ratios
0 Followers
Kidswell Bio Corporation Ratios
JP:4584's free cash flow for Q1 2026 was ¥0.00. For the 2026 fiscal year, JP:4584's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.72 | 1.55 | 2.07 | 3.50 | 2.97 |
| Quick Ratio | 2.55 | 1.21 | 1.70 | 2.90 | 2.08 |
| Cash Ratio | 1.53 | 0.69 | 0.94 | 1.01 | 1.04 |
| Solvency Ratio | -0.09 | -0.00 | -0.33 | -0.25 | -0.31 |
| Operating Cash Flow Ratio | -0.51 | 0.22 | -0.19 | -1.35 | -1.05 |
| Short-Term Operating Cash Flow Coverage | -3.02 | 1.43 | -0.62 | -3.79 | -15.59 |
| Net Current Asset Value | ¥ 1.41B | ¥ 1.10B | ¥ 670.14M | ¥ 1.04B | ¥ 1.53B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.42 | 0.26 | 0.51 | 0.50 | 0.20 |
| Debt-to-Equity Ratio | 1.54 | 1.30 | 3.10 | 1.58 | 0.41 |
| Debt-to-Capital Ratio | 0.61 | 0.57 | 0.76 | 0.61 | 0.29 |
| Long-Term Debt-to-Capital Ratio | 0.57 | 0.46 | 0.69 | 0.56 | 0.27 |
| Financial Leverage Ratio | 3.68 | 4.97 | 6.12 | 3.16 | 2.04 |
| Debt Service Coverage Ratio | -0.36 | 0.03 | -1.78 | -1.52 | -5.89 |
| Interest Coverage Ratio | -2.82 | 0.66 | -34.44 | -15.81 | -42.12 |
| Debt to Market Cap | 0.22 | 0.41 | 0.51 | 0.24 | 0.05 |
| Interest Debt Per Share | 53.26 | 46.43 | 73.95 | 62.70 | 23.19 |
| Net Debt to EBITDA | 5.39 | -9.96 | -0.25 | -1.42 | 0.87 |
| Profitability Margins | |||||
| Gross Profit Margin | 26.51% | 32.26% | 42.75% | 54.96% | 64.93% |
| EBIT Margin | -2.10% | 2.27% | -56.83% | -22.38% | -34.04% |
| EBITDA Margin | -2.10% | 2.29% | -56.80% | -22.35% | -33.90% |
| Operating Profit Margin | -2.10% | 0.55% | -54.93% | -19.84% | -41.49% |
| Pretax Profit Margin | -6.11% | 1.43% | -58.43% | -23.64% | -35.03% |
| Net Profit Margin | -6.28% | -0.42% | -58.49% | -23.68% | -35.10% |
| Continuous Operations Profit Margin | -6.28% | -0.42% | -58.49% | -23.68% | -35.10% |
| Net Income Per EBT | 102.75% | -29.01% | 100.11% | 100.18% | 100.22% |
| EBT Per EBIT | 290.90% | 261.33% | 106.36% | 119.11% | 84.41% |
| Return on Assets (ROA) | -6.80% | -0.30% | -27.96% | -16.88% | -15.87% |
| Return on Equity (ROE) | -25.03% | -1.50% | -171.03% | -53.30% | -32.35% |
| Return on Capital Employed (ROCE) | -3.52% | 1.04% | -49.28% | -19.41% | -27.60% |
| Return on Invested Capital (ROIC) | -3.22% | -0.24% | -38.74% | -17.14% | -26.75% |
| Return on Tangible Assets | -6.80% | -0.30% | -27.97% | -16.89% | -15.89% |
| Earnings Yield | -3.49% | -0.47% | -28.14% | -8.11% | -3.88% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.55 | 3.86 | 2.76 | 2.55 | 3.21 |
| Payables Turnover | 9.51 | 15.17 | 16.35 | 8.04 | 12.10 |
| Inventory Turnover | 13.32 | 2.33 | 1.59 | 1.97 | 0.56 |
| Fixed Asset Turnover | 374.02 | 4281.43 | 1841.84 | 1880.92 | 956.27 |
| Asset Turnover | 1.08 | 0.73 | 0.48 | 0.71 | 0.45 |
| Working Capital Turnover Ratio | 2.17 | 2.06 | 0.94 | 1.15 | 0.71 |
| Cash Conversion Cycle | 37.34 | 226.93 | 339.63 | 283.17 | 739.16 |
| Days of Sales Outstanding | 48.32 | 94.61 | 132.33 | 143.14 | 113.53 |
| Days of Inventory Outstanding | 27.40 | 156.39 | 229.63 | 185.43 | 655.79 |
| Days of Payables Outstanding | 38.39 | 24.06 | 22.33 | 45.40 | 30.16 |
| Operating Cycle | 75.72 | 250.99 | 361.96 | 328.57 | 769.32 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -22.40 | 23.13 | -12.83 | -44.90 | -37.91 |
| Free Cash Flow Per Share | -22.76 | 22.97 | -12.83 | -44.90 | -37.91 |
| Dividend Paid and CapEx Coverage Ratio | -62.06 | 145.36 | -1.00 | -1.00 | -7309.76 |
| Capital Expenditure Coverage Ratio | -62.06 | 145.36 | -1.00 | -1.00 | -7309.76 |
| Operating Cash Flow Coverage Ratio | -0.43 | 0.51 | -0.18 | -0.73 | -1.67 |
| Operating Cash Flow to Sales Ratio | -0.17 | 0.18 | -0.19 | -0.51 | -0.75 |
| Free Cash Flow Yield | -9.37% | 20.51% | -8.98% | -17.54% | -8.24% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -28.66 | -215.38 | -3.55 | -12.33 | -25.76 |
| Price-to-Sales (P/S) Ratio | 1.80 | 0.89 | 2.08 | 2.92 | 9.04 |
| Price-to-Book (P/B) Ratio | 7.17 | 3.22 | 6.08 | 6.57 | 8.33 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -10.68 | 4.88 | -11.14 | -5.70 | -12.13 |
| Price-to-Operating Cash Flow Ratio | -10.85 | 4.84 | -11.14 | -5.70 | -12.13 |
| Price-to-Earnings Growth (PEG) Ratio | -0.02 | 2.18 | -0.04 | -0.76 | 0.53 |
| Enterprise Value Multiple | -80.37 | 29.06 | -3.91 | -14.48 | -25.81 |
| Enterprise Value | 11.11B | 3.38B | 5.40B | 8.99B | 13.73B |
| EV to EBITDA | -80.37 | 29.06 | -3.91 | -14.48 | -25.81 |
| EV to Sales | 1.69 | 0.66 | 2.22 | 3.24 | 8.75 |
| EV to Free Cash Flow | -10.00 | 3.63 | -11.90 | -6.32 | -11.74 |
| EV to Operating Cash Flow | -10.17 | 3.61 | -11.90 | -6.32 | -11.74 |
| Tangible Book Value Per Share | 33.88 | 34.82 | 23.48 | 38.90 | 55.10 |
| Shareholders’ Equity Per Share | 33.89 | 34.84 | 23.52 | 38.97 | 55.20 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.03 | 1.29 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 135.05 | 125.47 | 68.79 | 87.71 | 50.86 |
| Net Income Per Share | -8.48 | -0.52 | -40.23 | -20.77 | -17.86 |
| Tax Burden | 1.03 | -0.29 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 2.91 | 0.63 | 1.03 | 1.06 | 1.03 |
| Research & Development to Revenue | 0.17 | 0.15 | 0.60 | 0.44 | 0.58 |
| SG&A to Revenue | 0.12 | 0.04 | 0.07 | 0.07 | 0.06 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.64 | -44.31 | 0.32 | 2.16 | 2.19 |
Currency in JPY
